Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Younger Indians have a 10 times higher rate of heart attack
Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
Medicines, including insulin, to be available in 40 lower-income countries
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Subscribe To Our Newsletter & Stay Updated